FDA — authorised 21 August 2025
- Application: NDA219407
- Marketing authorisation holder: IONIS PHARMS INC
- Indication: Type 1 - New Molecular Entity
- Status: approved
FDA authorised Dawnzera on 21 August 2025
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 21 August 2025; FDA has authorised it.
IONIS PHARMS INC holds the US marketing authorisation.